ML
CMPX icon

McAdam LLC’s Compass Therapeutics CMPX Stock Holding History

McAdam LLC’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.1K Buy
+16,494
New +$48.7K ﹤0.01% 513

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

McAdam LLC's CMPX Position: Q2 2026 in Review

McAdam LLC opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 16,494 shares worth $36.1K. The stake represents ﹤0.01% of the portfolio and ranks #513 among its holdings.

215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • McAdam LLC held 16,494 shares of Compass Therapeutics worth $36.1K as of Q2 2026.
  • Compass Therapeutics was a new McAdam LLC position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of McAdam LLC's portfolio in Q2 2026, its #513 holding.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on McAdam LLC's 13F filing for Q2 2026, filed 4 Aug 2026.